



Universiteit
Leiden
The Netherlands

Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches

Wu, Changsheng

Citation

Wu, C. (2016, October 26). *Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches*. Retrieved from <https://hdl.handle.net/1887/43768>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/43768>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/43768> holds various files of this Leiden University dissertation

Author: Wu, Shangsheng

Title: Discovery of novel antibiotics from actinomycetes by integrated metabolomics & genomics approaches

Issue Date: 2016-10-26

Chapter 2

Metabolomics in the natural products field – a gateway to novel antibiotics

Changsheng Wu^{1,2}, Hye Kyong Kim¹, Gilles P. van Wezel², and Young Hae Choi¹

¹*Natural Products Laboratory, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands*

²*Molecular Biotechnology, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands*

Drug Discov. Today Technol. **2015**, *13*, 11–17.

ABSTRACT

Metabolomics is a high throughput analytical technique used to globally measure low molecular weight metabolites, allowing simultaneous metabolic comparison of different biological samples and thus highlighting differential compounds as potential biomarkers. Though microbes are renowned as prolific sources of antibiotics, the traditional approach for new anti-infectives discovery is time-consuming and labor-intensive. In this review, the use of NMR- or MS-based metabolomics is proposed as an efficient approach to find antimicrobials in microbial single- or co-cultures.

1. INTRODUCTION


The number of multi-drug resistant bacteria is rising alarmingly and the treatment of infections caused by these microbes is extremely challenging.¹ Microorganisms are a renowned source of effective antibiotics. The traditional design of methods used for this research is considerably time and labor-intensive, and even worse is high rediscovery rate as much as 99.9%.¹ Thus, in view of the urgent need of new antibiotics, this search could be revitalized with a more efficient approach directed at speeding up the discovery process.

Metabolomics is a high throughput analytical technique used to globally measure low molecular weight metabolites in biological samples. Using a combination of chemical profiles built by LC-HRMS or NMR with multivariate data analysis (MDA), it is possible to compare and detect differential metabolites in active/inactive biological samples, narrowing the search to potential biomarkers and avoiding chemical redundancy in an early stage. In this paper, we have reviewed examples of the use of metabolomics as an effective tool to increase the efficiency of antibiotic discovery from microbial sources.

2. Metabolomics-guided discovery of new antibiotics

Metabolomics methodology, either NMR- or MS- based, is an ideal tool for the chemical screening and subsequent detailed comparison of the secondary metabolomes of a set of bacterial fermentations, rapidly revealing the differences/biomarkers among experimental groups. The next question is how to handle the compounds responsible for the separation in the score plot of supervised and/or unsupervised MDA. Since NMR and MS techniques can give structural information of compounds in an early stage, there are three possibilities for the identification of valuable biomarkers. Firstly, it is possible to compare the structural information provided by NMR (¹H NMR chemical shifts) and/or high-resolution mass spectrometry (molecular formula and isotopic pattern) with literature and/or databases. If known structures, discriminators can be identified without the need for time-consuming isolation process and thus metabolomics serves as an approach for dereplication; Another possible situation is the new compounds that possess known structural core but unknown functional groups—“known unknowns”. In this case, their structural characterization can be done within the context of the crude biological matrix with the aid of various 2D NMR techniques as reviewed.^{2,3} Besides this, the fragmentation patterns observed in the MS/MS spectra in conjunction with molecular networking evaluation can enable the identification of previously unknown close relatives within the same chemical families through spectral correlations;^{4,5} Last but not least, if the compounds have unprecedented nuclei, chromatographic isolation is inevitable for full *de novo* NMR structural characterization, but at the same time are the most promising in terms of truly new antimicrobials discovery. For this step, the discriminating signals generated in the comparative analysis (MDA) could be used as probes to track the target of interest (“star antibiotic”) throughout the chromatographic isolation, which is referred to as NMR-^{6,7} and/or MS-guided^{8,9} separation method. This can prevent losing track of the target that is unfortunately quite common in conventional TLC-guided isolation. Furthermore, some degree of structure identification, albeit incomplete, can be achieved beforehand with the 2D NMR measurements since they allow a partial prediction of the novel compounds. This can also provide information on chemical characteristics and help optimize isolation procedure, which makes sense for minimizing the

loss of compounds (e.g. ruling out the use of bare silica gel for polyphenolic polyketides due to their practically irreversible adsorption as in the case of clostrubin¹⁰). Taken together, the strategy of metabolomics-guided discovery of new antibiotics is illustrated in Scheme 1.



Scheme 1. Metabolomics-guided discovery of new antibiotics.

The use of metabolomics as a methodology for de-replication of known microbial secondary metabolites and prioritization of promising candidates is exemplified in the following cases. The LC-MS metabolome profiling of nine *Myxococcus* species allowed the rapid identification of known myxobacterial metabolites and the subsequent compound-based principal component analysis (PCA) was successfully highlighted the putative novel compound determined by its exact mass and isotopic pattern.¹¹ Tim S. Bugni¹² and his colleagues used UHPLC-HRMS-based metabolomics to dereplicate known structures and predict novel compounds in microbial crude extract. They then applied MS-guided separation approach to target the molecules highlighted by metabolomics analysis, and successfully discovered a series of antibiotics with novel skeletons, such as microtermolides,¹³

bottromycin D,¹⁴ and more recently forazoline A.¹⁵ Forazoline A (Figure 1) is a potent polyketide with a highly unusual skeleton, exhibiting *in vivo* antifungal efficacy against *Candida albicans* (MIC 16 µg/mL)—comparable to that of amphotericin B in a mouse model of *C. albicans* and no toxicity.¹⁵ Furthermore, they utilized a LC-MS-SPE-NMR hyphenation system that integrates MS-guided separation and *de novo* NMR structure elucidation¹⁶ to facilitate rapid structure elucidation of rare phenyl-acetyl-desferrioxamines indicated by metabolomics analysis.¹² In case of lowly abundant compounds, targeted LC-MS microisolation strategy reported by Jean-Luc Wolfender *et al.*^{17,18} for the purification of novel metabolites is necessary for full structure determination by means of microflow NMR analysis that just requires micrograms of compounds.^{19,20}




Figure 1. Structurally novel antibiotics discovered through the framework of metabolomics methodology.

3. Metabolomics applied to microbial cocultivation

Conventionally, scientists isolate pure strains of microbes collected from various biological samples, such as soil, marine sediments, symbionts of plants or sponges, *etc.* They then scale-up the single-strain fermentation under specific laboratory conditions to accumulate sufficient material for the next-stage systematical or bioassay-guided isolation. However, the isolation of novel antibiotics from microbes by means of this well-established routine is difficult. One of the reasons is many putative gene clusters remain silent under standard laboratory growth conditions when microbes are cultivated singly. Thus, it might be fruitful to consider not only single microorganism but more complex biological systems consisting of different organisms. This novel approach in which microbes are grown together (co-culture or confrontation experiments) has received increasing interest for its potential to produce new leads, and to decipher specific biosynthetic pathways mainly related to defense.²¹ The focus should be set on antagonistic interactions among the different microbes (fungi and/or bacteria) coexisting in the same defined environment, because they use chemical warfare consisting generally of small organic compounds for defense. In some cases, clear long-distance growth inhibition can be observed during pairwise co-culture on solid media. This phenomena is also expected to be linked to the production of antimicrobial compounds as a defense mechanism by one of the two co-inhabiting microorganisms.^{18,22} Coculturing the fungal endophyte *Fusarium tricinctum* with the bacterium *Bacillus subtilis* 168 trpC2 on solid rice medium resulted in up to 78 times the production of the fungal antibiotics enniatins A1 and B1.²³ Microbial cocultivation is also effective for the induction of new molecules with antimicrobial effect, as verified by the discovery of the new antibiotics pestalone²⁴, emericellamides A and

B,²⁵ *O*-methylmellein.²⁶ It is quite likely that one microbe produce molecules that could be precursors for biotransformation into other final products by its partner, which can increase the chemodiversity of induced metabolites and thus the chance of finding novel antibiotic.²⁷

Considering the great potential of cocultivation as a fertile source for new antibiotics, it is necessary to develop effective methods for their detection and identification of induced metabolites. Metabolomics is particularly appropriate for this purpose as indicated in ²². Untargeted generic fingerprinting using ¹H-NMR, but more by hyphenated MS methods (considered by some to be more powerful because of their sensitivity) is aimed to capture metabolites comprehensively. The comparison of the metabolome of the coculture with that of the individual microorganisms can highlight the induced metabolites present in coculture but absent in pure strains, since these *de novo*-produced molecules have high chances of being new compounds (even new skeletons) with antimicrobial activity. However, it is important to bear in mind that the conventional chemometric methods, such as PCA and (O)PLS-DA, are not absolutely ideal for coculture metabolomics studies, because they might not effectively filter the up-regulated metabolites in monocultures and thus not always highlight the coculture-induced metabolites specifically. A novel data mining approach referred to as projected orthogonalized chemical encounter monitoring (POChEMon) was recently developed and has proved to be more appropriate for this purpose.²¹

The detection of antibiotics using the microbial cocultivation strategy may be further revolutionized by the application of advanced analytical technologies introduced into metabolic profiling, one of which is imaging mass spectrometry (IMS).²⁸⁻³⁰ This technique can provide distinct chemical/structural data on the spatial distributions of metabolites directly on the agar Petri dishes avoiding complex sample pre-treatment.³¹⁻³⁴ For this, the antagonistic interaction between tested microorganisms is favored. After the antagonistic phenotypes are observed, the inhibition regions are subjected to IMS screening to visualize the metabolites. The microbial metabolites with a spatial distribution that is superimposed with the zone of inhibition are considered to be potential anti-infective candidates. The exact mass and isotope pattern provided by high resolution instruments such as MALDI-TOF-IMS, in combination with MS/MS network analysis can help estimate the structural novelty of the induced metabolites.^{4,35} This technique was applied in individual co-cultures of the pathogens *Staphylococcus aureus* and *Staphylococcus epidermidis* with *Streptomyces roseosporus* NRRL 15998. Using matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry, it was possible to observe the occurrence of three molecules (*m/z* 863, 877, and 891) that were responsible for the inhibition of both *Staphylococcus* pathogens. These stress-induced ions were subsequently identified as arylomycins, a class of broad-spectrum antibiotics that target type I signal peptidases.³⁶

4. Metabolomics reveals naturally occurring microbial interactions

Throughout thousands of years of evolution and survival adaption, microorganisms have established all types of close relationships with other organisms, including symbiosis, parasitism, competition and antagonism. Revealing the underneath molecular mechanisms involved in these “invisible” interactions would presumably contribute to the discovery of new chemical entities with antibiotic activity, because virulence factors in their natural contexts might turn out to have beneficial applications in human anti-infective therapy.³⁷

Particularly, deciphering the microbial pathogenesis of some ecologically relevant systems, such as associations with plants, mushrooms, insects, and sponges,³⁸ opens new perspectives for the exploration for new antimicrobials, as exemplified by the discovery of the novel antibiotics, rhizoxin³⁹ and desoxyhavannahine (Figure 2).⁴⁰ A very promising but yet quite unexplored reservoir for new antibiotics discovery is the insect-associated microbiome. As reviewed by Helge B. Bode,⁴¹ insects could be true pioneers as providers of anti-infectives for human beings. Paenilamicins (Figure 2), a class of novel hybrid nonribosomal peptide/polyketide antibiotics, were discovered in the bee pathogen, *Paenibacillus larvae*. Bee larval co-infection assays revealed that the paenilamicins are employed by *P. larvae* to fight ecological niche competitors and are not directly involved in mortality of the bee larvae.⁴²




Figure 2. Structures of several novel antibiotics discovered through the investigation of microbial interactions.

For cultivable symbionts, it could be expected that secondary metabolites produced in a natural context are probably different from those in a standard laboratory setting, since the growth condition considerably influences microbial secondary metabolism. Many cryptic biosynthetic gene clusters encoding molecules, remain silent in the laboratory setting due to the lack of appropriate environmental stimuli, and it is extremely challenging to mimic their natural environment in a laboratory. More so, many symbiotic microbes are not even amenable to artificial cultivation. In other words, antibiotics that would occur due to *in situ* microbial interactions are impossible to be discovered in a traditional culture-dependent

approach. Therefore, it is crucial to find a way to shed light on “hidden antibiotics” in a natural setting. The advances in metabolomics provide an opportunity to make what appeared to be impossible possible, using for example the above described IMS metabolome profiling techniques. The motile Gram-negative bacterium *Janthinobacterium agaricidamnosum* is known to be the causative agent of soft rot disease in the cultured button mushroom *Agaricus bisporus*. Driven by the hypothesis that the pathobiology of this mushroom pathogen was potentially correlated to antifungal search, MALDI-IMS was used for *in situ* profiling of the secondary metabolites harbored in the mushroom-associated ecological system of *Agaricus bisporus* vs *Janthinobacterium agaricidamnosum*. The visualization of a unique ion of m/z 1181 $[M+H]^+$ in the diseased region of the mushroom prompted the efforts to determine the structure of this compound and it was identified as an unprecedented cyclic lipopeptide product, jagaricin (Figure 2). Jagaricin turned out to be a fungicide that is highly active against human pathogenic fungi including *Candida albicans*, *Aspergillus fumigatus*, and *Aspergillus terreus* at submicromolar concentrations. Notably, jagaricin production by the bacterium *J. agaricidamnosum* tended to occur exclusively in the mushroom (*A. bisporus*) landscape and was otherwise impaired under a variety of regular laboratory cultivation conditions.⁴³ This example serves as a strong support for our arguments that understanding naturally-occurring microbial pathogenesis is beneficial for antibiotic search; and that IMS-based metabolomics can be applied to reveal the cryptic antibiotics that are only produced in a particular natural environment.

Revealing cryptic new antibiotics hidden in environmental samples might benefit from the surge in the development of single cell metabolomics, a tool used in metabolic analysis at cellular and subcellular level. As relevant perspectives of single cell metabolomics have been thoroughly reviewed just recently,⁴⁴⁻⁴⁶ our focus is to discuss its potential use in unveiling the metabolic communication between symbioses and hosts. Based on the morphological phenotypes or other properties such as fluorescence, the selective metabolic analysis of certain microbial cells in environmental samples could be used to view the unique secondary metabolites generated by involved microorganisms during the naturally occurring interspecies interactions. For instance, halogen *in situ* hybridization-secondary ion mass spectroscopy (HISH-SIMS) has allowed the simultaneous identification and quantitation of metabolic activities of environmental microbial assemblage at single-cell level without the need for traditional microbial separation and laboratory cultivation.⁴⁷ Single-cell mass spectrometry (SCMS) is a rapidly growing field in analytical chemistry, and there are a number of examples of its applicability to different cells.⁴⁴ In this case, the possibility of accurate mass measurement and acquiring structural information as provided by tandem MS, facilitate the identification of numerous metabolites from a single cell.

5. CONCLUSION

Metabolomics methods provide an innovative strategy for the discovery of new antibiotics from microbial sources. Allowing the comprehensive chemometric comparison of secondary metabolomes, it makes the dream of "finding a needle in a haystack" more realistic. The ability to measure the entire metabolomes within microorganisms that interact with hosts expressing cryptic gene clusters can be crucial for the exploitation of these untapped

reservoirs of potentially new anti-infectives.⁴⁸ Thus, metabolomics can be complementary to metagenomics methodology in accessing previously inaccessible natural products,⁴⁹ even has the advantage of delving into the biosynthetic potential of uncultivable microorganisms when applied to *in situ* analysis of live, undamaged biological tissues.

REFERENCES

- (1) Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. *Nat. Rev. Drug Discov.* **2007**, *6*, 29–40.
- (2) Kim, H. K.; Choi, Y. H.; Verpoorte, R. *Trends Biotechnol.* **2011**, *29*, 267–275.
- (3) Verpoorte, R.; Choi, Y. H.; Kim, H. K. *Phytochem. Rev.* **2007**, *6*, 3–14.
- (4) Watrous, J.; Roach, P.; Alexandrov, T.; Heath, B. S.; Yang, J. Y.; Kersten, R. D.; van der Voort, M.; Pogliano, K.; Gross, H.; Raaijmakers, J. M.; Moore, B. S.; Laskin, J.; Bandeira, N.; Dorrestein, P. C. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 1743–1752.
- (5) Sidebottom, A. M.; Johnson, A. R.; Karty, J. a; Trader, D. J.; Carlson, E. E. *ACS Chem. Biol.* **2013**, *8*, 2009–2016.
- (6) Grkovic, T.; Pouwer, R. H.; Vial, M.-L.; Gambini, L.; Noël, A.; Hooper, J. N. a; Wood, S. a; Mellick, G. D.; Quinn, R. J. *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 6070–6074.
- (7) Williams, D. E.; Dalisay, D. S.; Patrick, B. O.; Matainaho, T.; Andrusiak, K.; Deshpande, R.; Myers, C. L.; Piotrowski, J. S.; Boone, C.; Yoshida, M.; Andersen, R. J. *Org. Lett.* **2011**, *13*, 3936–3939.
- (8) Geng, C.-A.; Chen, X.-L.; Zhou, N.-J.; Chen, H.; Ma, Y.-B.; Huang, X.-Y.; Zhang, X.-M.; Chen, J.-J. *Org. Lett.* **2014**, *16*, 370–373.
- (9) Kersten, R. D.; Yang, Y.-L.; Xu, Y.; Cimermancic, P.; Nam, S.-J.; Fenical, W.; Fischbach, M. a; Moore, B. S.; Dorrestein, P. C. *Nat. Chem. Biol.* **2011**, *7*, 794–802.
- (10) Pidot, S.; Ishida, K.; Cyrulies, M.; Hertweck, C. *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 7856–7859.
- (11) Krug, D.; Zurek, G.; Schneider, B.; Garcia, R.; Müller, R. *Anal. Chim. Acta* **2008**, *624*, 97–106.
- (12) Hou, Y.; Braun, D. R.; Michel, C. R.; Klassen, J. L.; Adnani, N.; Wyche, T. P.; Bugni, T. S. *Anal. Chem.* **2012**, *84*, 4277–4283.
- (13) Carr, G.; Poulsen, M.; Klassen, J. L.; Hou, Y.; Wyche, T. P.; Bugni, T. S.; Currie, C. R.; Clardy, J. *Org. Lett.* **2012**, *14*, 2822–2825.
- (14) Hou, Y.; Tianero, M. D. B.; Kwan, J. C.; Wyche, T. P.; Michel, C. R.; Ellis, G. a; Vazquez-Rivera, E.; Braun, D. R.; Rose, W. E.; Schmidt, E. W.; Bugni, T. S. *Org. Lett.* **2012**, *14*, 5050–5053.
- (15) Wyche, T. P.; Piotrowski, J. S.; Hou, Y.; Braun, D.; Deshpande, R.; McIlwain, S.; Ong, I. M.; Myers, C. L.; Guzei, I. a.; Westler, W. M.; Andes, D. R.; Bugni, T. S. *Angew. Chemie Int. Ed.* **2014**, *53*, 11583–11586.
- (16) Seger, C.; Godejohann, M.; Tseng, L.-H.; Spraul, M.; Girtler, A.; Sturm, S.; Stuppner, H. *Anal. Chem.* **2005**, *77*, 878–885.

- (17) Glauser, G.; Guillarme, D.; Grata, E.; Boccard, J.; Thiocone, A.; Carrupt, P.-A.; Veuthey, J.-L.; Rudaz, S.; Wolfender, J.-L. *J. Chromatogr. A* **2008**, *1180*, 90–98.
- (18) Bertrand, S.; Schumpp, O.; Bohni, N.; Monod, M.; Gindro, K.; Wolfender, J.-L. *J. Nat. Prod.* **2013**, *76*, 1157–1165.
- (19) Wolfender, J.-L.; Queiroz, E. F.; Hostettmann, K. *Magn. Reson. Chem.* **2005**, *43*, 697–709.
- (20) Schroeder, F. C.; Gronquist, M. *Angew. Chem. Int. Ed. Engl.* **2006**, *45*, 7122–7131.
- (21) Bertrand, S.; Bohni, N.; Schnee, S.; Schumpp, O.; Gindro, K.; Wolfender, J.-L. *Biotechnol. Adv.* **2014**, *32*, 1180–1204.
- (22) Bertrand, S.; Schumpp, O.; Bohni, N.; Bujard, A.; Azzollini, A.; Monod, M.; Gindro, K.; Wolfender, J.-L. *J. Chromatogr. A* **2013**, *1292*, 219–228.
- (23) Ola, A.; Thomy, D. *J. Nat. Prod.* **2013**, *76*, 2094–2099.
- (24) Cueto, M.; Jensen, P.; Kauffman, C.; Fenical, W.; Lobkovsky, E.; Clardy, J. *J. Nat. Prod.* **2001**, *64*, 1444–1446.
- (25) Oh, D.-C.; Kauffman, C. a; Jensen, P. R.; Fenical, W. *J. Nat. Prod.* **2007**, *70*, 515–520.
- (26) Glauser, G.; Gindro, K.; Fringeli, J.; De Joffrey, J.-P.; Rudaz, S.; Wolfender, J.-L. *J. Agric. Food Chem.* **2009**, *57*, 1127–1134.
- (27) Scherlach, K.; Busch, B.; Lackner, G.; Paszkowski, U.; Hertweck, C. *Angew. Chemie* **2012**, *124*, 9753–9756.
- (28) Watrous, J. D.; Dorrestein, P. C. *Nat. Rev. Microbiol.* **2011**, *9*, 683–694.
- (29) Krug, D.; Müller, R. *Nat. Prod. Rep.* **2014**, *31*, 768–783.
- (30) Shih, C.-J.; Chen, P.-Y.; Liaw, C.-C.; Lai, Y.-M.; Yang, Y.-L. *Nat. Prod. Rep.* **2014**, *31*, 739–755.
- (31) Hsu, C.-C.; ElNaggar, M. S.; Peng, Y.; Fang, J.; Sanchez, L. M.; Mascuch, S. J.; Møller, K. a; Alazzeah, E. K.; Pikula, J.; Quinn, R. a; Zeng, Y.; Wolfe, B. E.; Dutton, R. J.; Gerwick, L.; Zhang, L.; Liu, X.; Månsson, M.; Dorrestein, P. C. *Anal. Chem.* **2013**, *85*, 7014–7018.
- (32) Watrous, J.; Hendricks, N.; Meehan, M.; Dorrestein, P. C. *Anal. Chem.* **2010**, *82*, 1598–1600.
- (33) Liu, W.-T.; Yang, Y.-L.; Xu, Y.; Lamsa, A.; Haste, N. M.; Yang, J. Y.; Ng, J.; Gonzalez, D.; Ellermeier, C. D.; Straight, P. D.; Pevzner, P. a; Pogliano, J.; Nizet, V.; Pogliano, K.; Dorrestein, P. C. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107*, 16286–16290.
- (34) Hoe, B. C.; Gorzelnik, K. V.; Yang, J. Y.; Hendricks, N.; Dorrestein, P. C. *Proc. Natl. Acad. Sci. U. S. A.* **2012**, *109*, 13082–13087.
- (35) Traxler, M. F.; Watrous, J. D.; Alexandrov, T.; Dorrestein, P. C.; Kolter, R. *MBio* **2013**, *4*, 1–12.
- (36) Liu, W.; Kersten, R.; Yang, Y. *J. Am. Chem. Soc.* **2011**, *133*, 18010–18013.
- (37) Schmidt, E. W. *Nat. Chem. Biol.* **2008**, *4*, 466–473.
- (38) Pidot, S. J.; Coyne, S.; Kloss, F.; Hertweck, C. *Int. J. Med. Microbiol.* **2014**, *304*, 14–22.
- (39) Partida-Martinez, L. P.; Hertweck, C. *Nature* **2005**, *437*, 884–888.
- (40) Kelman, D.; Kashman, Y.; Hill, R. T.; Rosenberg, E.; Loya, Y. *Pure Appl. Chem.* **2009**, *81*, 1113–1121.
- (41) Bode, H. B. *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 6394–6396.

-
- (42) Müller, S.; Garcia-Gonzalez, E.; Mainz, A.; Hertlein, G.; Heid, N. C.; Mösker, E.; van den Elst, H.; Overkleeft, H. S.; Genersch, E.; Süßmuth, R. D. *Angew. Chem. Int. Ed. Engl.* **2014**, *53*, 1–6.
- (43) Graupner, K.; Scherlach, K.; Bretschneider, T.; Lackner, G.; Roth, M.; Gross, H.; Hertweck, C. *Angew. Chem. Int. Ed. Engl.* **2012**, *51*, 13173–13177.
- (44) Rubakhin, S. S.; Lanni, E. J.; Sweedler, J. V. *Curr. Opin. Biotechnol.* **2013**, *24*, 95–104.
- (45) Trouillon, R.; Passarelli, M. K.; Wang, J.; Kurczy, M. E.; Ewing, A. G. *Anal. Chem.* **2013**, *85*, 522–542.
- (46) Zenobi, R. *Science (80-.)*. **2013**, *342*, 1201–1211.
- (47) Musat, N.; Halm, H.; Winterholler, B.; Hoppe, P.; Peduzzi, S.; Hillion, F.; Horreard, F.; Amann, R.; Jørgensen, B. B.; Kuypers, M. M. M. *Proc. Natl. Acad. Sci. U. S. A.* **2008**, *105*, 17861–17866.
- (48) Perić-Concha, N.; Long, P. F. *Drug Discov. Today* **2003**, *8*, 1078–1084.
- (49) Brady, S. F.; Simmons, L.; Kim, J. H.; Schmidt, E. W. *Nat. Prod. Rep.* **2009**, *26*, 1488–503.

